Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Efficacy and Safety of Fluoxetine in Treating Bipolar II Major Depressive Episode

Amsterdam, Jay D., Garcia-Espana, Felipe, Fawcett, Jan, Quitkin, Frederick M., Reimherr, Frederick W., Rosenbaum, Jerrold F., Schweizer, Edward, Beasley, Charles · 1998 · Journal of Clinical Psychopharmacology

Abstract

As many as 45% of patients with major depressive episode also meet DSM-IV criteria for bipolar II (BP II) disorder. Although some clinicians advocate using a mood stabilizer in treating BP II depression, antidepressant monotherapy has been less well studied in this disorder. As part of a prospective, placebo-controlled, relapse-prevention study in 839 patients, the efficacy and safety of short- and long-term fluoxetine treatment in patients with BP II major depression compared with patients with unipolar (UP) major depression was retrospectively examined. Eighty-nine BP II patients (mean age, 41+/-11 years) were compared with 89 age- and gender-matched UP patients and with 661 unmatched UP patients (mean age, 39+/-11 years). All received short-term fluoxetine therapy at 20 mg daily for up to 12 weeks. Complete remission was defined as a final Hamilton Rating Scale for Depression score < or = 7 by week 9 that was then maintained for 3 additional weeks. Remitted patients were then randomly assigned to receive double-blind treatment with one of the following: (1) fluoxetine 20 mg daily for 52 weeks; (2) fluoxetine for 38 weeks, then placebo for 14 weeks; (3) fluoxetine for 14 weeks, then placebo for 38 weeks; or (4) placebo for 52 weeks. Antidepressant efficacy was similar in BP and UP patients during short-term therapy. Discontinuation for lack of efficacy was lower in BP II (5%) than in UP (12%) patients (p = not significant [NS]), whereas dropouts for adverse events were similar in BP II (11%) and UP (9%) patients. During long-term relapse-prevention therapy, relapse rates were similar in BP II and UP patients (p = NS). During short-term fluoxetine therapy, three BP II (3.8%) versus no matched UP (p = NS) and 0.3% unmatched UP (p = 0.01) patients had a "manic switch." During long-term fluoxetine therapy, one (2%) BP II and three (1%) unmatched UP patients (one taking placebo) had a manic switch (p = NS). In conclusion, fluoxetine may be a safe and effective antidepressant monotherapy for the short-term treatment of BP II depression with a relatively low manic switch rate. Fluoxetine may also be effective in relapse-prevention therapy in patients with BP II disorder.

Overview

Integrity signals

Registry

Crossref · 10.1097/00004714-199812000-00003

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 23 references

Research works printed but not linked: 4

  1. Dunner, 1983, Psychiatr Dev, 1, 75
  2. Peselow, 1982, Psychiatr Clin (Basel), 15, 124
  3. Quitkin, 1981, Psychopharmacol Bull, 17, 142
  4. Kupfer, 1988, Arch Gen Psychiatry, 145, 804

Cited by

See all 167

Metadata

Authors
Amsterdam, J. D., Garcia-Espana, F., Fawcett, J., Quitkin, F. M., Reimherr, F. W., Rosenbaum, J. F., Schweizer, E., & Beasley, C.
Affiliations
Rush University Medical Center (US)
Venue
Journal of Clinical Psychopharmacology
Published
1998-12
Volume
18
Issue
6
Pages
435-440
ISSN
0271-0749 (ISSN-L)
OpenAlex
W2317383367
Cited by
167
References
23
Citations by year
2025: 2 · 2023: 2 · 2021: 1 · 2019: 4 · 2018: 2 · 2017: 1 · 2016: 5 · 2015: 3 · 2014: 6 · 2013: 7 · 2012: 3
FWCI
5.66
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Clinical Psychology › Personality Disorders and Psychopathology
Keywords
bipolar II disorder, major depressive episode, fluoxetine, antidepressant monotherapy, manic switch, relapse prevention, unipolar major depression, treatment efficacy, drug safety, adverse events, remission, mood stabilizers, long-term maintenance therapy, relapse rate
MeSH terms
Adolescent, Adult, Aged, Bipolar Disorder, Child, Double-Blind Method, Female, Fluoxetine, Headache, Humans, Sleep Initiation and Maintenance Disorders, Male, Middle Aged, Recurrence, Retrospective Studies, Treatment Outcome, Age of Onset, Antidepressive Agents, Second-Generation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Fluoxetine in Treating Bipolar II Major Depressive Episode. https://app.cochat.ai/papers/10.1097/00004714-199812000-00003
The paper
Amsterdam, J. D., Garcia-Espana, F., Fawcett, J., Quitkin, F. M., Reimherr, F. W., Rosenbaum, J. F., Schweizer, E., & Beasley, C. (1998). Efficacy and Safety of Fluoxetine in Treating Bipolar II Major Depressive Episode. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199812000-00003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.